Diagnostic follow‐up of indeterminate pulmonary nodules in the Medicare population

Abstract

AbstractBackgroundManagement of indeterminate pulmonary nodules (IPNs) is associated with redistribution of lung cancer to earlier stages, but most subjects with IPNs do not have lung cancer. The burden of IPN management in Medicare recipients was assessed.MethodsSurveillance, Epidemiology, and End Results–Medicare data were analyzed for IPNs, diagnostic procedures, and lung cancer status. IPNs were defined as chest computed tomography (CT) scans with accompanying International Classification of Diseases (ICD) codes of 793.11 (ICD‐9) or R91.1 (ICD‐10). Two cohorts were defined: persons with IPNs during 2014–2017 comprised the IPN cohort, whereas those with chest CT scans without IPNs during 2014–2017 comprised the control cohort. Excess rates of various procedures due to reported IPNs over 2 years of follow‐up (chest CT, positron emission tomography [PET]/PET‐CT, bronchoscopy, needle biopsy, and surgical procedures) were estimated using multivariable Poisson regression models comparing the cohorts adjusted for covariates. Prior data on stage redistribution associated with IPN management were then used to define a metric of excess procedures per late‐stage case avoided.ResultsTotals of 19,009 and 60,985 subjects were included in the IPN and control cohorts, respectively; 3.6% and 0.8% had lung cancer during follow‐up. Excess procedures per 100 persons with IPNs over a 2‐year follow‐up were 63, 8.2, 1.4, 1.9, and 0.9 for chest CT, PET/PET‐CT, bronchoscopy, needle biopsy, and surgery, respectively. Corresponding excess procedures per late‐stage case avoided were 48, 6.3, 1.1, 1.5, and 0.7 based on an estimated 1.3 late‐stage cases avoided per 100 IPN cohort subjects.ConclusionsThe metric of excess procedures per late‐stage case avoided can be used to measure the benefits‐to‐harms tradeoff of IPN management.